Tidal Investments’s Pacira BioSciences PCRX Stock Holding History

Tidal Investments’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8,411	Closed	-$218K	–	2519
2025 Q4	$218K	Buy	+8,411	New	+$200K	﹤0.01%	1977
2025 Q2	–	Sell	-19,217	Closed	-$478K	–	2030
2025 Q1	$478K	Sell	19,217 -1,590	-8%	-$38.1K	﹤0.01%	1349
2024 Q4	$392K	Sell	20,807 -1,038	-5%	-$18.2K	﹤0.01%	1498
2024 Q3	$329K	Hold	21,845	–	–	﹤0.01%	1563
2024 Q2	$625K	Buy	+21,845	New	+$622K	0.01%	1171

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Tidal Investments's PCRX Position: Q1 2026 in Review

Tidal Investments sold out of Pacira BioSciences (PCRX) in Q1 2026, closing a stake of 8,411 shares — an estimated $218K sold.

Tidal Investments first reported a position in PCRX in Q2 2024 and held it in 5 quarters. The position peaked at $625K in Q2 2024. 242 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

Tidal Investments reported no remaining Pacira BioSciences position as of Q1 2026 after selling out during the quarter.
Tidal Investments sold 8,411 Pacira BioSciences shares in Q1 2026, an estimated $218K.
Tidal Investments first reported a position in Pacira BioSciences in Q2 2024 and held it in 5 quarters.
Tidal Investments's Pacira BioSciences position peaked at $625K in Q2 2024.
242 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Tidal Investments's 13F filing for Q1 2026, filed 15 May 2026.